VolitionRx Limited

What they do

VolitionRx Limited, a Delaware corporation based in Henderson, Nevada, develops epigenetics-based diagnostic tests built on its Nucleosomics platform. Its product pillars include Nu.Q Vet for animal diagnostics, Nu.Q Lung Cancer for human cancer detection, and the Capture-Seq liquid biopsy technology, along with a collaboration with Sysmex Corporation related to Neutrophil Extracellular Traps. Operations are run through wholly owned subsidiaries in Singapore, Belgium, and the UK, plus a majority-owned veterinary diagnostics subsidiary.

Revenue drivers

• Nu.Q Vet (veterinary diagnostics) — The company's commercial veterinary testing franchise, reported as a third species with a feline lymphoma prototype assay submitted for peer review in May; a publication is expected to unlock a $5 million contractual milestone payment.
• Human diagnostics / Nu.Q — Human-use tests centered on Nu.Q Lung Cancer, being advanced toward reimbursement with Hospices Civils de Lyon; no routine clinical use or reimbursement revenue is yet reported.
• Licensing and collaboration arrangements — Management said it is in discussions and technology evaluations with more than a dozen diagnostic and liquid biopsy companies, targeting upfront milestone payments, royalties and/or recurring revenue, though no specific license agreements are quantified in the excerpts.
• Capture-Seq liquid biopsy technology — An earlier-stage pillar for which the company announced its first peer-reviewed publication; no revenue contribution is stated.

Recent performance

First half 2026 revenue was $1.4 million, up 112% over the first half of 2025, though second quarter 2026 revenue of approximately $0.4 million was roughly flat year over year. XBRL quarterly revenue was $398,657 for the quarter ended June 30, 2026, versus $985,076 in the prior quarter. Operating expenses fell 32% year over year in the second quarter and operating loss was $4.2 million, down 34%, reflecting the cost reduction program. Net cash used in operating activities was $5.2 million in the quarter. The second quarter included $1.2 million of net proceeds from at-the-market equity sales and $4.1 million from a confidentially marketed public offering of shares and warrants.

Strategy

Management describes a licensing-led model, aiming to convert evaluations with diagnostic and liquid biopsy companies into agreements producing upfront milestones, royalties or recurring revenue. Near-term clinical priorities include the feline Nu.Q Vet lymphoma publication and the Nu.Q Lung Cancer reimbursement submission with Hospices Civils de Lyon. The company continues building data rooms with published and confidential data across its pillars, including the first peer-reviewed Capture-Seq paper. It has cut operating costs and funded itself through at-the-market sales, confidentially marketed offerings, and other equity issuances reported in 8-K filings between June and September 2026. Management cites a total addressable market estimated at more than $27 billion across all product pillars.

Risks

• Going-concern / balance sheet — At June 30, 2026 the company reported total liabilities of $41.8 million against total assets of $8.3 million, negative shareholder equity of $32.2 million, and only $2.8 million of cash and equivalents.
• No approved routine clinical revenue — Human Nu.Q products are still pre-reimbursement and pre-routine-use, so reported revenue of $1.4 million in the first half of 2026 is small relative to ongoing operating losses.
• Dependence on licensing negotiations — Management states its revenue strategy relies on converting discussions with more than a dozen companies into signed licensing agreements, which are not yet executed beyond the existing Sysmex collaboration.
• Continued dilution from equity issuance — The company funded the second quarter of 2026 through at-the-market sales and a confidentially marketed offering, and 8-K filings show further unregistered equity sales in June, August and September 2026, with shares outstanding rising from 8,087,955 on April 28, 2026 to 13,649,384 on August 11, 2026.

Outlook

Management points to the expected peer-reviewed publication of the feline Nu.Q Vet lymphoma study, which it says should unlock a $5 million contractual milestone payment, and to the Nu.Q Lung Cancer reimbursement submission with Hospices Civils de Lyon as the path to first routine clinical use. It also flags further licensing agreements across its pillars as the primary commercial objective, without specifying timing or amounts.